Furthermore, we tested several dual EHMT1/2 inhibitors in prostate cancer models, and UNC0642 (23) stood out as a potential inhibitor that decreases prostate cancer tumor growth and metastasis in vivo. Here, EHMT1 is linked to prostate carcinoma.